Notice: file_put_contents(): Write of 10137 bytes failed with errno=28 No space left on device in /var/www/tg-me/post.php on line 50
Readhub | Telegram Webview: readhub_cn/247142 -
Telegram Group & Telegram Channel



tg-me.com/readhub_cn/247142
Create:
Last Update:

亿帆医药:全资子公司获得氨溴特罗口服溶液药品注册证书

亿帆医药全资子公司宿州亿帆药业获得氨溴特罗口服溶液药品注册证书,该产品用于治疗急性和慢性呼吸道疾病。此次注册证书的获得将丰富公司产品线,提升公司在药品领域的竞争力,对业绩产生积极影响,但具体经营情况受多因素影响,存在不确定性。

媒体报道
亿帆医药:全资子公司获得氨溴特罗口服溶液药品注册证书 财联社/钛媒体
亿帆医药:氨溴特罗口服溶液获药品注册证书 第一财经
亿帆医药(002019.SZ):获得氨溴特罗口服溶液的药品注册证书 金融界

事件追踪
2025-03-10 仁和药业:子公司获得盐酸莫西沙星滴眼液药品注册证书
2025-03-06 复星医药:药品丁二酸复瑞替尼胶囊注册申请获受理
2025-03-05 华东医药:全资子公司收到医疗器械注册申请受理通知书
2025-03-03 华润双鹤:左乙拉西坦口服溶液获药品注册证书
2025-02-27 复星医药(600196.SH):盐酸溴己新注射液药品注册申请获受理
2025-02-20 华东医药:全资子公司收到药品注册受理通知书
2025-02-12 华东医药:全资子公司收到药品注册受理通知书
2025-02-05 复星医药:控股子公司药品获欧盟上市批准
2025-01-24 复星医药:控股子公司获药品注册申请受理
2025-01-20 福元医药:全资子公司乳果糖口服溶液获得药品注册证书

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/247142

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.

Tata Power whose core business is to generate, transmit and distribute electricity has made no money to investors in the last one decade. That is a big blunder considering it is one of the largest power generation companies in the country. One of the reasons is the company's huge debt levels which stood at ₹43,559 crore at the end of March 2021 compared to the company’s market capitalisation of ₹44,447 crore.

Readhub from hk


Telegram Readhub
FROM USA